Navigation Links
DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference

REHOVOT, Israel, May 29, 2007 /PRNewswire/ -- D-Pharm announced today that the results of the Phase IIb trial for its neuroprotective compound DP-b99 in the treatment of acute ischemic stroke patients will be presented at the European Stroke Conference. The data will be presented by the study's German principal investigator Prof. H. C. Diener, on Thursday May 31st at 14.30 in the Carron Room, at the Scottish Exhibition Conference Center in Glasgow. The abstract for the presentation may be viewed using the European Stroke Conference search engine at: http://www.eurostroke.eu/gla_searching.htm

DP-b99, discovered and developed by D-Pharm, is a unique neuroprotective drug that addresses an array of damaging processes occurring in the brains of stroke patients. A Phase IIb multicenter, double blind, placebo controlled, randomized trial to assess DP-b99's effect on stroke outcomes was completed in December 2006. The study enrolled 150 ischemic stroke patients with signs of cortical involvement and NIH Stroke Scale (NIHSS) score of 7-20. DP-b99 (1mg/kg/day) or placebo was administered i.v. within 1-9 hours of stroke-onset as a 4-day course of once-daily 2hr infusions with a 90-day follow-up.

The main pre-defined efficacy endpoints in the study included: the change in National Institute of Health Stroke Scale (NIHSS) score from day 0 to day 90; the percent of patients completely recovered after stroke (score 0 or 1, or same as pre-stroke) at day 90 as assessed by the modified Rankin scale or NIHSS.

The day 90 recovery rate in the DP-b99 treated group was two times higher than in the placebo group. Specifically, the recovery rate in the DP-b99 and placebo groups per modified Rankin scale was 30.6% and 16.0% (p=0.05), per NIHSS was 23.6% and 12.0% (p=0.08), and defined by either scale was 37.5% and 18.7% (p=0.02), respectively
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Phase IIb Trial Results Presented the European Stroke Conference
(Date:5/22/2013)... , May 22, 2013  Healthcare providers ... enterprise content management (ECM) solution, for ... Information System .  These organizations identified enterprise ... and will use OnBase to optimize their ... (Logo:  http://photos.prnewswire.com/prnh/20090130/65710LOGO  ) ...
(Date:5/22/2013)... , May 22, 2013 STEPh, Inc., ... announce the launch of their web site ( ... Reports].  About STEPh Reports ... development.  Each STEPh Report assesses the ... data, projected launch year, company, and specific key issues.  ...
(Date:5/22/2013)... Ohio , May 22, 2013   Life ... health screening services announced today the creation of a ... (MCM) . MCM is a population ... to MCM,s growing list of clients. These important expanded ... costly chronic conditions earlier. Effective prevention reduces cost of ...
Breaking Medicine Technology:Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Life Line Screening and MCM Solutions for Better Health Announce New Partnership 2
... DAYTON, Ohio, Dec. 15 Robbins & Myers, Inc. (NYSE: ... its fiscal 2010 first quarter ending November 30, 2009, before the ... webcast is scheduled for Wednesday, January 6, 2010, at 2:30 ... Officer, and Christopher M. Hix, Vice President and Chief Financial Officer, ...
... , ST. LOUIS, Dec. 15 KV Pharmaceutical ... the Company received a written notice (the "Notice") executed by ... of the Company, requesting that the Board of Directors of ... action by written consent relating to the proposed appointment of ...
Cached Medicine Technology:KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 7
(Date:5/22/2013)... 22, 2013 Phelps Memorial Hospital Center ... Westchester Lung Nodule Center for individuals who would like ... care. Lung cancer is the deadliest form of cancer for ... the U.S. die from lung cancer than from breast, colon ... early detection increases survival rates. It is well established ...
(Date:5/22/2013)... 22, 2013 Hurricane preparation isn’t just ... That’s why Amica Insurance is reminding everyone ... upcoming hurricane season. , “An important part of hurricane ... a senior assistant vice president at Amica Insurance. “The ... the threat of a storm.” , Flood damage is ...
(Date:5/22/2013)... Daytona Beach, FL (PRWEB) May 22, 2013 ... have signed on as a sponsor for this weekend's I ... will take place at 8:00 am at Cocoa Riverside Park ... the community through the I Talk to Strangers social movement. ... team of runners and walkers to participate in the event. ...
(Date:5/22/2013)... HR Strategies recently participated in the Gwinnett Relay ... on Friday May 10, 2013. For never having participated ... over $6,300 for cancer research. , HR Strategies ... first $3,000 for Bronze Level Sponsorship. HR Strategies CEO, ... match the company’s contribution of $3,000; and after just ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Unknown to the ... area at 30 mph. Minutes before it struck, the ... the nearing threat. This gave them time to reach safety ... Data is proud to provide a product that will ... A Wheelock SAFEPATH® SP40S Emergency Evacuation System provides ...
Breaking Medicine News(10 mins):Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:Reviewing Insurance Policies: a Key Part of Hurricane Preparations 2Health News:Space Girl Organics to Sponsor May 25 Miracle Run/Walk 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2
... devastating neurodegenerative disorders such as Huntington,s disease has been ... the use of cutting-edge genetic techniques. Led by ... Lisbon (led by Dr Tiago Outeiro) and University of ... collaborated to generate novel approaches for tackling the diseases. ...
... January 10, 2011 -- While most blood tests require shipping ... several days for the results, a new device invented by a ... uses just a pinprick of blood in a portable device that ... a big step in point-of-care diagnostics, where testing can be performed ...
... Steven Reinberg HealthDay Reporter , FRIDAY, Jan. 7 ... amount of fluoride in the nation,s drinking water should now ... is a significant help in preventing cavities and tooth decay, ... teeth. About two out of five teens have white spots ...
... Jenifer Goodwin HealthDay Reporter , FRIDAY, Jan. 7 (HealthDay ... skin come to mind, but new research finds that skin isn,t ... facial bones, which lose volume and recede, making you look even ... the bones of the eye socket gradually widen, the brow bone ...
... 2011) Just 5 percent of Parkinson,s disease cases can ... known cause. But a new discovery by researchers at The ... to explain why the vast majority of Parkinson,s patients develop ... Journal of Neuroscience , the researchers demystified a process that ...
... on information to predict their future health, and may be ... a national survey conducted by researchers at Tufts Medical Center, ... hypothetical predictive test to find out if they will later ... average, respondents were willing to pay $300 to $600, depending ...
Cached Medicine News:Health News:New hope in fight against Huntington's disease 2Health News:Engineering team invents lab-on-a-chip for fast, inexpensive blood tests 2Health News:U.S. Officials Recommend Reduced Fluoride Levels in Water 2Health News:Age Takes Toll on Facial Bones, Study Finds 2Health News:Age Takes Toll on Facial Bones, Study Finds 3Health News:Scientists shed light on what causes brain cell death in Parkinson's patients 2Health News:Most consumers want predictive tests to learn if a disease is in their future 2Health News:Most consumers want predictive tests to learn if a disease is in their future 3
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... concave seats and large backrests with lumbar ... armrests, and casters and glides. • Choose ... a variety of environments including: industry, education, ... and office. • With tubular base • ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • Not available with casters • With Tubular Base....
Medicine Products: